Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Change in Account Payables (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Change in Account Payables for 16 consecutive years, with $258850.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 299.06% to $258850.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $1.0 million, a 336.07% increase, with the full-year FY2025 number at $1.0 million, up 336.07% from a year prior.
  • Change in Account Payables was $258850.0 for Q4 2025 at Cryo Cell International, down from $370475.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $735107.0 in Q1 2025 to a low of -$931007.0 in Q1 2024.
  • A 5-year average of $95669.2 and a median of $180209.0 in 2023 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 754.22% in 2021; the steepest drop was 901.73% in 2021.
  • Cryo Cell International's Change in Account Payables stood at $490656.0 in 2021, then plummeted by 138.18% to -$187349.0 in 2022, then soared by 174.02% to $138669.0 in 2023, then tumbled by 193.77% to -$130035.0 in 2024, then surged by 299.06% to $258850.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Change in Account Payables are $258850.0 (Q4 2025), $370475.0 (Q3 2025), and -$364175.0 (Q2 2025).